Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

A reminder to all members that you agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


20 Pages (Click to Jump) V  < 1 2 3 4 5 6 7 > »    
 
  
Reply to this topic

PEB, PACIFIC EDGE BIOTECHNOLOGY LIMITED
plastic
post Posted: Nov 8 2011, 09:50 AM
  Quote Post


Posts: 10,267
Thanks: 302


Can't understand why they are developing a lab in the US when according to the PR yesterday they have no patent issuance there. They give no status on uptake of product in markets they have entered. Margins or royalties per sale. Don't even tell us how they are marketing the thing.

Yet they just keep on diluting the hell out of everyone making big promises. Not good enough unless your one of the yes-men running the show.

The cancer is not in the bladder for this company.



--------------------
What did Uncle Mel do to us?
 
plastic
post Posted: Aug 28 2011, 01:36 PM
  Quote Post


Posts: 10,267
Thanks: 302


Mystery men in Superlife Trustee Nominees are making their move. Holding went up 1646% some time in last two weeks.

Maybe they will finally transact.



--------------------
What did Uncle Mel do to us?
 
plastic
post Posted: Mar 29 2011, 07:02 AM
  Quote Post


Posts: 10,267
Thanks: 302


In Reply To: Kookaburra's post @ Dec 21 2010, 06:16 AM

If you expect perennial disappointment you will not be disappointed with this one. As the article says, how can they be so dumb?

It is now about 15 months since they were giving interviews in the media telling everyone they expect to have deals done by last March.

As far as diagnostics go, I think CIR offers far better prospects.

QUOTE
Still on the subject of cancer, biotech minnow Pacific Edge has told the NZX it has signed a deal with Australian healthcare provider Healthscope to market its diagnostic technology for bladder cancer across the Tasman.

This is good news for Pacific Edge, although how good is hard to say.

It's the first commercial deal for the technology, called Cxbladder, which allows the early detection of bladder cancer from a small urine sample.

Bladder cancer is a serious problem – the ninth most prevalent cancer generally and the fourth most prevalent in in men. According to Pacific Edge, about 50,000 people in Australia will go to their doctor this year complaining of blood in the urine, a condition called haematuria and a potential cancer indicator (10-20 per cent of them may turn out to have the disease).

The company hopes Cxbladder will ultimately be the main initial diagnostic test, and be used alongside other more invasive tests, such as biopsy and cytoscopy.

A clinical study completed in February last year, quoted in its annual report, suggests the product works better than other techniques, particularly a rival product called NMP22 marketed by a subsidiary of US healthcare giant Alere.

The question is, how much money will it make?

On this point Pacific Edge is vague. It says the Australian healthcare system will "invest" $50 million a year investigating haematuria, but doesn't say how much of that market could go to Cxbladder.

It also says treatment of bladder cancer has the highest medical costs of any cancer – a cost in the US estimated at US$200,000 from diagnosis to death - but again doesn't say what slice of that expenditure could go on a test such as Cxbladder.

Details of the revenue share with Healthscope are also not given, on the grounds that it is commercially sensitive.

Pacific Edge, as shareholders will be painfully aware, has burnt through $22.7 million in developing its products and has yet to say when that money will begin to be recouped.

To be fair, that's relatively small beer for a biotech, but for a company reliant on maintaining investor goodwill Pacific Edge seems remarkably unfriendly.

As well as the absence of meaningful information on its prospects, Pacific Edge keeps its financial reports password-protected on its website, apparently to keep them from the prying eyes of its competitors.

But since anyone can ring up and ask for a password, this must be utterly useless in deflecting competitors, but highly effective for annoying interested investors.

How could a smart company be so dumb?




--------------------
What did Uncle Mel do to us?
 
Kookaburra
post Posted: Dec 21 2010, 06:16 AM
  Quote Post


Posts: 6


In Reply To: plastic's post @ Dec 3 2010, 12:17 PM

wrong people and wrong product - i do not think they will surprise at all

 
plastic
post Posted: Dec 3 2010, 12:17 PM
  Quote Post


Posts: 10,267
Thanks: 302


Now they are saying they will seek world domination in diagnostics on $4.5m. Wish these people would get real. Someone should knock on their door and tell them ROSG is going cheap at the moment. They have a distribution network set up already, specialist labs in Philly and operate in the same space. A RTO of them with a pharma partnership would put some meat on the bones and give NASDAQ exposure but I don't think these guys are up to it.

But you never know they may surprise.

QUOTE
Pacific Edge's commercialisation strategy will be to develop and run diagnostic laboratories in selected geographies initially offering the bladder cancer detection technology and then adding the colorectal cancer prognostic product. Negotiations with investors and business partners continue for the development of centralised service laboratories and 'turn-key' licensees in Europe and the US.




--------------------
What did Uncle Mel do to us?
 
plastic
post Posted: Nov 5 2010, 02:08 PM
  Quote Post


Posts: 10,267
Thanks: 302


Looks like PEB won't amount to much. Their partner CDY is where its at. The sooner PEB is put down the better I say. And there they were at the beginning of the year telling us all they will transact shortly. See they are still issuing shares to keep the wages paid.

http://www.asx.com.au/asxpdf/20101103/pdf/31tn3064pxqxn0.pdf

QUOTE
Midkine is an embryonic cytokine that is attracting wide interest as a cancer biomarker and potential diagnostic and prognostic tool. Midkine has very limited expression in healthy adults, but is detectable in high quantities in the blood and urine of patients with a wide variety of cancers.

Midkine levels have also been found to correlate with progression and malignancy in certain cancers. Validation data on midkine as a suitable biomarker for cancerdetection and prognosis is the subject of over 50 peer reviewed publications.

Cellmid holds key patents in all major territories for the use of midkine in the earlydetection, diagnosis and prognosis of cancer.

Cellmid has to date licensed its technology to two companies for the development of lung and bladder cancer diagnostic tests.





--------------------
What did Uncle Mel do to us?
 

Featured Stock Stories





plastic
post Posted: Oct 23 2010, 07:04 AM
  Quote Post


Posts: 10,267
Thanks: 302


The ability of PEB to pull something like this out of their hat I think is beyond them. Instead, I fear they will just be left to wither on the vine until its IP and expertise is plucked.

http://finance.yahoo.com/news/GE-Healthcar...ml?x=0&.v=1

QUOTE
CHALFONT ST GILES, UK and ALISO VIEJO, Calif., Oct. 22 /PRNewswire-FirstCall/ -- GE Healthcare, a unit of General Electric Company (NYSE:GE - News), and Clarient, Inc. (Nasdaq:CLRT - News) announced today that they have entered into a definitive agreement for GE Healthcare to acquire Clarient, a leading player in the fast-growing molecular diagnostics sector. Clarient's technologies, combined with GE Healthcare's strengths in diagnostic imaging, are expected to accelerate the development of new integrated tools for the diagnosis and characterization of cancer. A subsidiary of GE will commence a tender offer for all outstanding common and preferred shares of Clarient at $5.00 per common share and $20.00 per preferred share, in each case payable in cash.






--------------------
What did Uncle Mel do to us?
 
plastic
post Posted: Aug 25 2010, 03:23 PM
  Quote Post


Posts: 10,267
Thanks: 302


Still nothing out of these guys. But if we are to put a positive slant on things, the AGM is tomorrow and they may actually front up and provide the flesh on what they have been up to. I note also PYC is in a trading halt pending detail on a cap. raising. The thing they have in common is the Roche element.

Maybe we will see the colour of a Roche franc tomorrow.

Lets hope so, the alternative is just more of the same and that is a joke gone bad now.



--------------------
What did Uncle Mel do to us?
 
plastic
post Posted: Jul 7 2010, 01:36 PM
  Quote Post


Posts: 10,267
Thanks: 302


With the amount of cash they can realistically expect to raise, compare to BPO for example, is put against their expectations below clearly they are just jerking people around.

I would be much more supportive if they were to get rid of the CEO and some of the more expensive staff. This SPP is for no other purpose except to keep them in their lifestyles.


Pacific Edge is raising funds through the Share Purchase Plan (SPP) to existing shareholders to continue the commercialisation of the Company's recently completed bladder cancer detection product, Cxbladder in Australasia, USA and Europe. Pacific Edge will also be completing the colorectal cancer prognostic gene signature to a market ready product position and continuing the development of other products in late stage development in the Company's product pipeline. The Company could reasonably expect that these funds will enable these products to enter the market and start the product revenue for the Company.



--------------------
What did Uncle Mel do to us?
 
anselll
post Posted: Jul 7 2010, 10:38 AM
  Quote Post


Posts: 179
Thanks: 17


In Reply To: plastic's post @ Jul 5 2010, 03:28 PM

Until the dude selling at below the SPP price disappears nothing much is going to happen to the plan!

 
 


20 Pages (Click to Jump) V  < 1 2 3 4 5 6 7 > » 

Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING